These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 36933565)

  • 41. Nirmatrelvir and ritonavir combination against COVID-19 caused by omicron BA.2.2 in the elderly: A single-center large observational study.
    Chen C; Li R; Xing S; Cao L; Qu Y; Lv Q; Li X; Chen Z
    Immun Inflamm Dis; 2024 Apr; 12(4):e1232. PubMed ID: 38578027
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors of nirmatrelvir-ritonavir receipt among COVID-19 patients in a large US health system.
    Malden DE; McLaughlin JM; Hong V; Lewnard J; Ackerson BK; Puzniak L; Kim JS; Takhar H; Frankland TB; Slezak JM; Tartof SY
    Sci Rep; 2024 Mar; 14(1):7485. PubMed ID: 38553527
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk.
    Paraskevis D; Gkova M; Mellou K; Gerolymatos G; Psalida N; Gkolfinopoulou K; Kostaki EG; Loukides S; Kotanidou A; Skoutelis A; Thiraios E; Saroglou G; Zografopoulos D; Filippou D; Mossialos E; Zaoutis T; Gaga M; Tsiodras S; Antoniadou A
    J Infect Dis; 2023 Dec; 228(12):1667-1674. PubMed ID: 37565522
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparing the effectiveness of molnupiravir and nirmatrelvir-ritonavir in non-hospitalized and hospitalized COVID-19 patients with type 2 diabetes: A target trial emulation study.
    Wan EYF; Wong ZCT; Yan VKC; Chui CSL; Lai FTT; Li X; Wong ICK; Chan EWY
    Diabetes Obes Metab; 2024 Oct; 26(10):4653-4664. PubMed ID: 39109461
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data.
    Petrakis V; Rafailidis P; Trypsianis G; Papazoglou D; Panagopoulos P
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112956
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A retrospective cohort study of prescribing outcomes in outpatients treated with nirmatrelvir-Ritonavir for COVID-19 in an interdisciplinary community clinic.
    Leung V; Gill S; Llanes A; Khawaja A; Stagg A; McCready J; Jacubovich M; Ho G; Powis J; Kandel C
    PLoS One; 2023; 18(10):e0293302. PubMed ID: 37856531
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19.
    Hammond J; Yunis C; Fountaine RJ; Luscan G; Burr AM; Zhang W; Wisemandle W; Soares H; Baniecki ML; Hendrick VM; Kalfov V; Pypstra R; Rusnak JM
    N Engl J Med; 2024 Jul; 391(3):224-234. PubMed ID: 39018532
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Short-term Pregnancy Outcomes After Nirmatrelvir-Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19).
    Loza A; Farias R; Gavin N; Wagner R; Hammer E; Shields A
    Obstet Gynecol; 2022 Sep; 140(3):447-449. PubMed ID: 36356238
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
    Hammond J; Leister-Tebbe H; Gardner A; Abreu P; Bao W; Wisemandle W; Baniecki M; Hendrick VM; Damle B; Simón-Campos A; Pypstra R; Rusnak JM;
    N Engl J Med; 2022 Apr; 386(15):1397-1408. PubMed ID: 35172054
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative effectiveness of combination therapy with nirmatrelvir-ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir-ritonavir in patients hospitalised with COVID-19: a target trial emulation study.
    Choi MH; Wan EYF; Wong ICK; Chan EWY; Chu WM; Tam AR; Yuen KY; Hung IFN
    Lancet Infect Dis; 2024 Nov; 24(11):1213-1224. PubMed ID: 39025098
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reprint of: Evaluation of physicians prescribing of COVID-19 guideline-directed outpatient treatments in a primary care walk-in clinic.
    Denning K; Sheppard J; Carico R
    J Am Pharm Assoc (2003); 2024; 64(4S):102158. PubMed ID: 39127938
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission.
    Wee LE; Tay AT; Chiew C; Young BE; Wong B; Lim R; Lee CL; Tan J; Vasoo S; Lye DC; Tan KB
    Clin Microbiol Infect; 2023 Oct; 29(10):1328-1333. PubMed ID: 37331509
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
    Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
    BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oral Nirmatrelvir-Ritonavir Use and Clinical Outcomes in Pregnant Patients With Coronavirus Disease 2019 (COVID-19).
    Toure BB; Panakam A; Johns SL; Butler SK; Tuomala RE; Diouf K
    Obstet Gynecol; 2024 Feb; 143(2):273-276. PubMed ID: 37963387
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents.
    Gentry CA; Nguyen PN; Thind SK; Kurdgelashvili G; Williams RJ
    Clin Infect Dis; 2024 Feb; 78(2):330-337. PubMed ID: 37619991
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
    Saravolatz LD; Depcinski S; Sharma M
    Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022.
    Harrington PR; Cong J; Troy SB; Rawson JMO; O'Rear JJ; Valappil TI; McGarry Connelly S; Farley J; Birnkrant D
    MMWR Morb Mortal Wkly Rep; 2023 Dec; 72(51):1365-1370. PubMed ID: 38127674
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nirmatrelvir-Ritonavir and COVID-19 Mortality and Hospitalization Among Patients With Vulnerability to COVID-19 Complications.
    Dormuth CR; Kim JD; Fisher A; Piszczek J; Kuo IF
    JAMA Netw Open; 2023 Oct; 6(10):e2336678. PubMed ID: 37782496
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nirmatrelvir-ritonavir therapy and COVID-19 vaccination improve clinical outcomes of SARS-CoV-2 Omicron variant infection.
    Qi T; Jin Y; Wang H; Liao Y; Liu T; Mao E; Li F; Li Y; Fan X; Ling Y
    J Med Virol; 2023 Feb; 95(2):e28497. PubMed ID: 36651302
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia.
    Low EV; Pathmanathan MD; Ten YY; Chidambaram SK; Kim WR; Lee WJ; Teh ZW; Appannan MR; Ismail M; Samad AA; Peariasamy KM
    BMC Infect Dis; 2024 Aug; 24(1):780. PubMed ID: 39103829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.